The deadline to submit an abstract for short talk consideration has passed.  For any questions or issues, please email info@keystonesymposia.org.

This  Keystone Symposium will focus on advances in the rapidly evolving field of targeted protein degradation (TPD). In the past five years this field has moved from proof of concept to the development of degrader drugs in clinical trials. Clinical impact has brought a sense of urgency and broadened interest for formulating and clarifying a new science of degradation. TPD has focused on cullin ring ligases and their substrate receptors cereblon and VHL with other degradation pathways such as autophagy, ERAD, heat shock chaperones and monovalent degraders, etc, also emerging as part of the TPD field. Currently small molecule degraders induce the formation of non-native protein-protein interactions. It is in the context of discoveries of the mechanistic details that drive ternary complex formation and the sharing of these developments that this field will continue to gain momentum. To elaborate the biophysics, chemistry, cell biology and genetic basis for this new science, the TPD symposia will assemble leaders from around the world to share insights across diverse disciplines. There will a strong emphasis on renewing the spirit of face to face exchanges among subject matter experts with the idea to maximize interactions, formulate questions and foster new collaborations. Importantly, this meeting will be held jointly with the Keystone Symposium on Proximity Based Therapeutics, to leverage the synergy between these two fields in terms of translating basic science into therapeutic potential.